Making Every Stride Count - Adequan® Steps Up As Title Sponsor

Monday, February 7, 2011
Posted by Equestrian Sport Productions


Luitpold Pharmaceuticals, Inc., makers of Adequan® i.m. (polysulfated glycosaminoglycan) the official joint therapy of the US Equestrian Federation is excited to return for the second year as a weekly sponsor of FTI WEF.
Allyn Mann, Senior Manager of the Animal Health Division of Luitpold Pharmaceuticals reports, "The audience at FTI WEF is one of our prime users because of what the horses go through day in and out in show jumping competition. There are probably 120 vets who come in from all over the US to be involved with the horses competing here. We know that our product gets a lot of use with jumpers and hunters, and they understand the benefits of a product like Adequan®."

"The number one priority for our company is to educate the veterinarian, horse owner, trainer and rider about the value of identifying joint problems early in the disease process," states Allyn Mann, Sr. Manager at Luitpold Pharmaceuticals, Inc. "Our new marketing campaign for 2011 is based on a simple yet powerful message":

Check your horse's legs daily for joint swelling or heat.

Joint problems can begin with a misstep, incorrect shoeing or abnormal stresses on the joint. This abnormal pressure creates additional wear on the joint and inflammation of the joint tissue. When symptoms appear, the horse's joint has already sustained damage. Catching any imbalance in the joint early will improve your horse's chances of regaining full mobility.

Many veterinarians agree that preventing lameness is their goal. Call your veterinarian when any abnormal signs appear, or if your horse is hesitant to perform.

Treat problems early before the disease process has the opportunity to damage cartilage.

Detecting and treating joint problems before cartilage and /or bone damage occurs can prolong the working life of the performance or pleasure horse.  

Early treatment means less damage to the joint. When degenerative joint disease is detected, destructive enzymes have already started attacking and breaking down the cartilage. You can treat the pain and decrease the swelling with rest and pain medicine, but that's just suppressing the symptoms not curing the problem.

Adequan® i.m. (polysulfated glycosaminoglycan) is the only FDA approved treatment that will not only stop joint disease, but reverse damage by restoring synovial fluid in the joint and stimulating cartilage repair.

Reverse the damage by using Adequan® (polysulfated glycosaminoglycan), the only FDA approved disease modifying osteoarthritic drug available for treating equine joints.

Only Adequan® i.m. (polysulfated glycosaminoglycan) stimulates cartilage repair and reverses traumatic joint dysfunction. The only FDA approved disease modifying osteoarthritic drug available for equine joints, nearly doubles the hyaluronic acid concentration in the joint fluid within 48 hours after a single intramuscular injection. It is detected in cartilage and subchondral bone up to 4 days after being injected in the muscle.

To get the maximum benefit from Adequan i.m., administer 1 dose every 4 days for 7 treatments.

For more information visit

There are no known contraindications to the use of intramuscular polysulfated glycosaminoglycan or PSGAG in horses. Studies have not been conducted to establish safety in breeding horses. Not for use in horses intended for food.

The 2011 FTI Winter Equestrian Festival has 12 weeks of top competition running from January 12 through April 3. WEF is run by Equestrian Sport Productions, LLC, and Wellington Equestrian Partners and held at the Palm Beach International Equestrian Center. All 12 shows are "AA" rated and Jumper Rated 6, and more than $6 million in prize money will be awarded.

WEF is proud to be supported by their title sponsor, FTI Consulting, Inc. FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations protect and enhance enterprise value in an increasingly complex legal, regulatory and economic environment. With more than 3,600 employees located in most major business centers in the world, they work closely with clients every day to anticipate, illuminate, and overcome complex business challenges in areas such as investigations, mergers and acquisitions, regulatory issues, reputation management and restructuring. For more information, please visit

Please visit or call 561-793-5867 for more information.